Brian Topp
Merck & Co.
14 Papers
18 Citations
Brian Topp is an academic researcher from Merck & Co.. The author has contributed to research in topics: Medicine & Internal medicine. The author has an hindex of 2, co-authored 8 publications.
Chat about Author
Papers
Preclinical QSP Modeling in the Pharmaceutical Industry: An IQ Consortium Survey Examining the Current Landscape.
Marjoleen Nijsen,Fan Wu,Loveleena Bansal,Erica L. Bradshaw-Pierce,Jason R. Chan,Bianca M. Liederer,Jerome T. Mettetal,Patricia Schroeder,Edgar Schuck,Alice Tsai,Christine Xu,Anjaneya Chimalakonda,Kha Le,Mark Penney,Brian Topp,Akihiro Yamada,Mary E. Spilker +16 more
- 01 Mar 2018
TL;DR: The survey results provide insights on the current state of preclinical QSP modeling in addition to future opportunities, and call attention to the need for an aligned definition and consistent terminology around QSP.
66
Applications of Quantitative Systems Pharmacology in Model-Informed Drug Discovery: Perspective on Impact and Opportunities.
Erica L. Bradshaw,Mary E. Spilker,Richard Zang,Loveleena Bansal,Handan He,Rhys D.O. Jones,Kha Le,Mark Penney,Edgar Schuck,Brian Topp,Alice Tsai,Christine Xu,Marjoleen Nijsen,Jason R. Chan +13 more
- 01 Nov 2019
TL;DR: Quantitative systems pharmacology approaches have been increasingly applied in the pharmaceutical since the landmark white paper published in 2011 by a National Institutes of Health working group brought attention to the discipline.
64
Lesion-level heterogeneity of radiologic progression in patients treated with pembrolizumab.
TL;DR: Lesion-level heterogeneity at the time of disease progression was common in pembrolizumab-treated patients, with many patients demonstrating ongoing disease control in a subset of tumor sites.
19
Tumor dynamics in patients with solid tumors treated with pembrolizumab beyond disease progression.
Brian Topp,Madhav Channavazzala,Kapil Mayawala,Dinesh P. de Alwis,Eric Rubin,Alexandra Snyder,Jedd D. Wolchok,Antoni Ribas +7 more
TL;DR: Pembrolizumab generates meaningful efficacy in a subset of patients treated beyond RECIST v1.1 progression, and most patients show stable target lesion dynamics in the post-progression period.
19
Beyond the single average tumor: Understanding IO combinations using a clinical QSP model that incorporates heterogeneity in patient response.
Rukmini Kumar,Kannan Thiagarajan,Lakshmanan Jagannathan,Liming Liu,Kapil Mayawala,Dinesh P. de Alwis,Brian Topp +6 more
- 01 Jul 2021
TL;DR: In this article, a quantitative system pharmacology model for metastatic melanoma was developed for immuno-oncology with the goal of predicting efficacy of combination checkpoint therapy with pembrolizumab and ipilimumab.
14